Biotech Firms Pursue Alternatives While IPOs Remain Cold
With the initial public offerings market slumping, more life sciences companies are exploring alternative ways to relieve their cash crunch, ranging from cost-cutting to seeking private financing or exploring partnerships and...To view the full article, register now.
Already a subscriber? Click here to view full article